Back to Search
Start Over
Clonal chromosomal abnormalities appearing in Philadelphia chromosome–negative metaphases during CML treatment
- Source :
- Blood. 130:2084-2091
- Publication Year :
- 2017
- Publisher :
- American Society of Hematology, 2017.
-
Abstract
- Clonal chromosomal abnormalities in Philadelphia chromosome-negative (CCA/Ph-) metaphases emerge as patients with chronic phase chronic myeloid leukemia (CP-CML) are treated with tyrosine kinase inhibitors (TKIs). We assessed the characteristics and prognostic impact of 598 patients with CP-CML treated on clinical trials with various TKIs. CCA/Ph- occurred in 58 patients (10%); the most common were -Y in 25 (43%) and trisomy 8 in 7 patients (12%). Response to TKI therapy was similar for patients with CCA/Ph- and those without additional chromosomal abnormalities (ACAs). We further categorized CCA/Ph- into those in which -Y was the only clonal abnormality, and all others. We found that patients with non -Y CCA/Ph- had worse failure-free survival (FFS), event-free survival (EFS), transformation-free survival (TFS), and overall survival (OS) compared with those without ACAs with the following 5-year rates: FFS (52% vs 70%, P = .02), EFS (68% vs 86%, P = .02), TFS (76% vs 94%, P < .01), and OS (79% vs 94%, P = .03). In a multivariate analysis, non -Y CCA/Ph- increased the risk of transformation or death when baseline characteristics were considered with a hazard ratio of 2.81 (95% confidence interval, 1.15-6.89; P = .02). However, this prognostic impact was not statistically significant when achieving BCR-ABL
- Subjects :
- Male
medicine.medical_specialty
Pathology
Immunology
Philadelphia chromosome
Trisomy 8
Biochemistry
Gastroenterology
Disease-Free Survival
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
hemic and lymphatic diseases
Internal medicine
medicine
Chromosomes, Human
Humans
Prospective Studies
Survival rate
Metaphase
Chromosome Aberrations
business.industry
Ponatinib
Hazard ratio
Cell Biology
Hematology
medicine.disease
Survival Rate
Dasatinib
chemistry
Nilotinib
030220 oncology & carcinogenesis
Chromosome abnormality
Female
business
030215 immunology
medicine.drug
Subjects
Details
- ISSN :
- 15280020 and 00064971
- Volume :
- 130
- Database :
- OpenAIRE
- Journal :
- Blood
- Accession number :
- edsair.doi.dedup.....bc92adf28f2a09c5b4d55b3f0ffc6174